| 摘要: |
| 目的 探讨Sonazoid超声造影和普美显增强磁共振在肝细胞肝癌中的诊断价值。方法 回顾性分析2021年6月至2023年12月因肝脏占位性病变于我院就诊并进行Sonazoid超声造影检查和普美显增强磁共振检查的患者资料，分析肝脏占位性病变在两种影像学检查中各个时相的增强特征。以患者手术或穿刺病理结果，或大于6个月的临床随访结果为“金标准”，分别计算Sonazoid超声造影检查和普美显增强磁共振检查在HCC诊断中的准确率、敏感度、特异度。并采用Kappa检验对其一致性进行检验。结果 以手术或穿刺病理结果，或大于6个月的临床随访结果为“金标准”，Sonazoid超声造影和普美显增强磁共振诊断肝脏占位性病变为HCC的准确性、灵敏度、特异度分别为87.27%、90.24%、78.57%；90.91%、92.68%、85.71%。两者之间相比P值大于0.05，差异无统计学意义。Sonazoid超声造影和普美显增强磁共振的一致性检验Kappa值=0.908，一致性较好。结论 Sonazoid超声造影和普美显增强磁共振诊断肝脏占位性病变为肝细胞肝癌的诊断效能相比P值大于0.05，差异无统计学意义。两者的一致性检验Kappa值=0.908，一致性较好。作为新型肝脏特异性超声诊断对比剂，Sonazoid对肝脏占位性病变的诊断与普美显增强磁共振具有可类比的临床价值，可以作为另一种较为可靠的诊断肝脏局灶性病变的影像学检查而广泛应用于临床。 |
| 关键词: Sonazoid 普美显增强磁共振 肝脏占位性病变 超声造影。 |
| DOI： |
| 投稿时间：2024-01-08修订日期：2024-02-20 |
| 基金项目:无锡市卫生健康委员会科研项目(Q202142) |
|
| The diagnostic value of Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging in hepatocellular carcinoma |
| Zhang Yu,Ding Yan,Tang Qunfeng,Gu Chengyu,Zhou Fengsheng |
| (Department of Ultrasound Medicine,Wuxi People''s Hospital Affiliated to Nanjing Medical University,Jiangsu Wuxi) |
| Abstract: |
| Objective To explore the diagnostic value of Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging in hepatocellular carcinoma. Methods Retrospective analysis the patient data from June 2021 to December 2023 at our Hospital who underwent Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging for liver space occupying lesions. Analyzing the enhancement characteristics of liver space occupying lesions at different stages in two imaging examinations. Taking the surgical or puncture pathology results, or clinical follow-up results greater than 6 months as the "gold standard", calculating the accuracy, sensitivity, and specificity of Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of HCC respectively. And use Kappa test to verify its consistency. Results Taking the surgical or puncture pathology results, or clinical follow-up results greater than 6 months as the "gold standard", the accuracy, sensitivity, and specificity of Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging in diagnosing liver mass lesions as HCC were 87.27%, 90.24%, 78.57% and 90.91%, 92.68%, 85.71% respectively. There is no statistically significant difference between the two test, with a P-value greater than 0.05. The consistency test between Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging showed a Kappa value of 0.908, indicating good consistency. Conclusion The consistency test between Sonazoid contrast-enhanced ultrasound and gadoxetic acid-enhanced magnetic resonance imaging showed that there is no statistically significant difference between the two test, with a P-value greater than 0.05. The Kappa value is 0.908 which indicates good consistency. So as a new type of liver specific ultrasound diagnostic contrast agent, Sonazoid has a comparable clinical value in the diagnosis of liver space occupying lesions with gadoxetic acid-enhanced magnetic resonance imaging. It can be widely used in clinical practice as another reliable imaging examination for diagnosing focal liver lesions. |
| Key words: Sonazoid Gadoxetic acid-enhanced magnetic resonance imaging Liver space occupying lesions Contrast-enhanced ultrasound. |
